Clifford Chance has advised Heilpflanzenwohl AG on the deal. Heilpflanzenwohl AG finalized the acquisition of two OTC products, “Döderlein” and “Omniflora”, from Haleon Sarl. The project...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised Hitachi Ltd. on the deal. Hitachi Ltd. has signed a stock purchase agreement to acquire all shares of MA micro automation GmbH from...
You must be a Standard 1 Year member to access this content.
Baker McKenzie advised Minoryx Therapeutics on the deal. Clifford Chance advised the Neuraxpharm Group. Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments...
You must be a Standard 1 Year member to access this content.
Orrick Herrington & Sutcliffe advised AXA Investment Managers on the deal. Clifford Chance LLP advised the consortium and Sullivan & Cromwell LLP advised GS Infrastructure. Latham...
You must be a Standard 1 Year member to access this content.
